Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") announces that its stock and convertible bonds (hereinafter referred to as "convertible bonds") have been decided to be delisted by the Shenzhen Stock Exchange (hereinafter referred to as "SZSE"). The delisting will enter a trading period for delisting arrangements starting from April 28, 2025, lasting for fifteen trading days, with the last trading day being May 21, 2025. The Company's stock and convertible bonds will be officially delisted on May 22, 2025.
According to Article 30 of the "Management Regulations for Convertible Bonds of Delisted Companies," convertible bonds cannot be converted, redeemed, or sold back during the period from delisting to the time they are managed by the National Equities Exchange and Quotations (NEEQ) in the delisted sector (hereinafter referred to as "delisted sector"). Investors who have submitted applications for conversion, redemption, or sale back that have not been completed before delisting must resubmit their applications after the convertible bonds are listed in the delisted sector.
The designated media and contact information for the Company's information disclosure after delisting are as follows:
Contact person: Securities Department
Phone: 0898-66661090
Email: securities@hnpoly.com
Address: Economic Development Zone, Meilan District, Haikou City, Hainan Province
Designated information disclosure media: Giant Tide Information Network (www.cninfo.com.cn) or the official website of the share transfer system (www.neeq.com.cn)
Since February 9, 2025, the Company's convertible bonds have entered the repurchase period (the last two interest-bearing years). The Company and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
During the repurchase period, if the Company's stock closes below 70% of the current conversion price for any consecutive thirty trading days, the Company may face early repayment requests for part of the principal and interest of the convertible bonds, which may result in the risk of not being able to repay in full. On April 18, 2025, the Company received the SZSE's decision on the termination of listing for Hainan Puli Pharmaceutical Co., Ltd.'s stock and convertible bonds (Shenzhen Stock Exchange [2025] No. 357).